Connected data gives you a clearer picture
At Evaluate we collect, calibrate and connect the pharmaceutical world's data.
Thought Leadership
Latest Report
Pharma’s Biggest Spenders 2022 Infographic
As several of the big 11 pharma companies dialled back on acquisitions, the collective bill for M&A and R&D activities among this cohort took a dip for the second consecutive year in 2022, even as Pfizer marched on with its spending spree. Their collective expenditure – $157 billion – might be the smallest since 2018, but it's still a…
Report library
ASCO: Skirmishes Break Out In The Great Lung Cancer Battle
Report Highlights For prescribers, at least, it is becoming ever more important to stay up to date with the numerous subgroups into which first-line NSCLC is being…
EP Vantage Pharma, Biotech and Medtech 2017 In Review
Report Highlights All major healthcare indices climbed in 2017, echoing wider stock market strength The $80bn spent on pharma & biotech acquisitions in 2017 makes…
EP Vantage 2018 Preview
Report Highlights M&A activity expected to climb after slow 2017 – US tax reform a deciding factor for big deals Another big year predicted for venture financing…
Evaluate Forecasting Excellence: The Value of Outliers in Consensus Forecasting
Key Report Themes Upside/downside radio metrics that identify companies that could either outperform in the coming years or are at risk Companies that could follow a…
